Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX101 versus standard of care in adults with Wilson disease
2017-004135-36Phase 3Unknown
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Wilson disease (WD) comparing WTX101 with Standard of care (2 arms). Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2017-004135-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004135-36.